HBM HOLDINGS-B (02142.HK): NMPA Accepts IND Application of HBM7004 for Advanced Solid Tumors

NewTimeSpace News: Hbm Holdings Limited (02142.HK) released a voluntary announcement on June 10, 2026, stating that the National Medical Products Administration (NMPA) has accepted the IND application for HBM7004, a novel B7H4xCD3 bispecific antibody targeting advanced solid tumors.
Derived from the Group's proprietary HBICE^® platform, HBM7004 delivers differentiated solutions for cancer immunotherapy in terms of efficacy and safety. Preclinical studies have demonstrated that HBM7004 activates T cells in a B7H4-dependent manner within tumors. In multiple animal models, it exhibits potent anti-tumor activity, excellent in-vivo stability and low systemic toxicity.
The Group previously announced on May 8, 2026 that the U.S. FDA had approved the IND application for HBM7004, authorizing the launch of its first-in-human Phase I clinical trial in the United States. The acceptance by NMPA marks another major progress following the FDA's approval.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.